Nature Medicine, Published online: 11 November 2026; doi:10.1038/s41591-026-04768-x Several deaths during trials of experimental cell and gene therapies in China appear to reveal gaps in governance and oversight. A new layer of independent external review is needed for clinical supervision of high-risk therapies.
Li Du, Kalina Kamenova, Zhangyu Wang, Meng Wang, Yujuan Li, Ruipeng Lei et al. Lessons from recent investigator-initiated trials of gene-editing therapies in China. // Nature Medicine. – 2026. – DOI: 10.1038/s41591-026-04768-x. – URL: https://www.nature.com/articles/s41591-026-04768-x
Li Du, Kalina Kamenova, Zhangyu Wang, Meng Wang, Yujuan Li, Ruipeng Lei, & Xi Zhang (2026). Lessons from recent investigator-initiated trials of gene-editing therapies in China. Nature Medicine. https://doi.org/10.1038/s41591-026-04768-x
Li Du, et al. “Lessons from recent investigator-initiated trials of gene-editing therapies in China.” Nature Medicine, 2026. doi:10.1038/s41591-026-04768-x.
@article{Du2026,
title = {Lessons from recent investigator-initiated trials of gene-editing therapies in China},
author = {Du, Li and Kamenova, Kalina and Wang, Zhangyu and Wang, Meng and Li, Yujuan and Lei, Ruipeng and Zhang, Xi},
journal = {Nature Medicine},
year = {2026},
doi = {10.1038/s41591-026-04768-x},
url = {https://www.nature.com/articles/s41591-026-04768-x}
}
ABSTRACT As leadership education continues to evolve, increasing attention has been given to fostering learners’ leadership identity, capacity, and efficacy. Drawing on collaborative conversations with 12 leadership educators...